Search results
Showing 616 to 630 of 1070 results for drug therapy
Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)
Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.
Evidence-based recommendations on radiotherapy for age-related macular degeneration. This involves using radiation to destroy the new blood vessels, with the aim of slowing down sight loss.
View recommendations for HTG24Show all sections
Sections for HTG24
Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.
This guideline covers integrated diagnostic reporting for diagnosing haematological cancer in adults, young people and children. It also covers staffing, facilities (levels of care) and multidisciplinary teams needed for adults and young people. It aims to improve care for people with suspected or diagnosed cancer by promoting best practice on the organisation of haematological cancer services.
View recommendations for NG47Show all sections
MMprofiler for prognostic risk classification in multiple myeloma (MIB270)
NICE has developed a medtech innovation briefing (MIB) on MMprofiler for prognostic risk classification in multiple myeloma .
Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)
Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus.
Transpupillary thermotherapy for age-related macular degeneration (HTG31)
Evidence-based recommendations on transpupillary thermotherapy for age-related macular degeneration. This involves using a laser to heat and seal up the blood vessels that are causing the problems.
View recommendations for HTG31Show all sections
Sections for HTG31
Autism spectrum disorder in adults: diagnosis and management (CG142)
This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)
Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin and prednisolone for untreated diffuse large B-cell lymphoma in adults.
This quality standard covers recognising, assessing and managing bipolar disorder in adults (aged 18 and over) in primary and secondary care. It describes high-quality care in priority areas for improvement.
View quality statements for QS95Show all sections
Sections for QS95
- Quality statements
- Quality statement 1: Referral for specialist mental health assessment
- Quality statement 2: Personalised care plan
- Quality statement 3: Involving carers in care planning
- Quality statement 4 (developmental): Psychological interventions
- Quality statement 5: Maintaining plasma lithium levels
- Quality statement 6: Valproate
- Quality statement 7: Assessing physical health
Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on LQD Spray for treating acute and chronic wounds .
This guideline covers alcohol problems among people over 10. It aims to prevent and identify such problems as early as possible using a mix of policy and practice.